Dermata Therapeutics, Inc. (DRMA) News
Filter DRMA News Items
DRMA News Results
|Loading, please wait...|
Latest DRMA News From Around the Web
Below are the latest news stories about Dermata Therapeutics Inc that investors may wish to consider to help them evaluate DRMA as an investment opportunity.
Good morning, trader!
Gainers: Dermata Therapeutics DRMA +35%. Innoviva (INVA) +11%. Mainz Biomed (MYNZ) +9%. Regional Health Properties RHE +9%. Envista Holdings (NVST) +8%.Losers: InfuSystem
Thinking about buying stock in Dermata Therapeutics, Ironnet, Preferred Apartment Communities, Mattel, or Viking Therapeutics?
NEW YORK , Feb. 10, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DRMA, IRNT, APTS, MAT, and VKTX. Full story available on Benzinga.com
IceCure Medical ICCM +16%. Atossa Therapeutics (ATOS) +15%. Dermata Therapeutics (DRMA) -31%. Statera Biopharma STAB -26%.
Dermata Therapeutics Inc (NASDAQ: DRMA ) has requested the FDA to waive the requirements to complete a 90-day dermal minipig study and a standard dermal pharmacokinetics study before the End of Phase 2 meeting for its DMT310 acne program. The Company said it has already planned and budgeted to conduct both studies. The requests come as DMT310 has been used in clinical trials by over 170 patients exhibiting an acceptable safety and tolerability profile. Further, the FDA approved the Company … Full story available on Benzinga.com
SAN DIEGO, CA / ACCESSWIRE / January 13, 2022 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata," or the "Company"), a clinical-stage biotechnology company focused on the treatment of medical and aesthetic skin conditions, today announced the appointment of Brittany Bradrick to its Board of Directors and its Audit Committee.
SAN DIEGO, CA / ACCESSWIRE / January 5, 2022/ Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced that Gerry Proehl, Dermata's Chairman of the Board, President, and Chief Executive Officer, will present a company overview at the H.
Wall Street analysts forecast that Dermata Therapeutics Inc (NASDAQ:DRMA) will post earnings per share of ($0.25) for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Dermata Therapeutics earnings. The firm is scheduled to issue its next quarterly earnings report on Monday, December 27th. On average, analysts expect that Dermata Therapeutics 
Analysts Offer Insights on Healthcare Companies: Werewolf Therapeutics (HOWL) and Dermata Therapeutics (DRMA)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Werewolf Therapeutics (HOWL – Research Report) and Dermata Therapeutics (DRMA – Research Report) with bullish sentiments. Werewolf Therapeutics (HOWL) H.C. Wainwright analyst Michael King reiterated a Buy rating on Werewolf Therapeutics today and set a price target of $32.00. The company's shares closed last Wednesday at $14.65. According to TipRanks.
Dermata Therapeutics (NASDAQ:DRMA) was downgraded by Zacks Investment Research from a hold rating to a sell rating in a research report issued on Tuesday, Zacks.com reports. According to Zacks, Dermata Therapeutics Inc. is a privately held biotechnology company. It focused on treatment of medical and aesthetic skin diseases and conditions. The companys product pipeline consist